Sound excitable drugs

声音兴奋药物

基本信息

批准号：
7994102
负责人：
CHING-HSUAN TUNG
金额：
$ 30.8万
依托单位：
METHODIST HOSPITAL RESEARCH INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-09-01 至 2014-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7994102
关键词：
Ablation Adenocarcinoma Affect Aleurites Apoptotic Area Cancer cell line Carcinoma Cell Culture Techniques Cells Cessation of life Chemicals Clinical Cytotoxic agent Development Disease Dose Drug Design Evaluation Experimental Designs Fibroblasts Focused Ultrasound Therapy Future Generations Glioma Goals Image Kidney Lead Light Liver Malignant Neoplasms Malignant neoplasm of brain Mus Necrosis Neuroblastoma Optics Pancreas Pathway interactions Pharmaceutical Preparations Photochemotherapy Phototoxicity Porphyrins Principal Investigator Process Radiation Radiation therapy Reaction Time Reactive Oxygen Species Renal Cell Carcinoma Reporter Research Safety Series Side Site Structure Technology Therapeutic Tissues Toxic effect Translations Ultrasonic wave Ultrasonography Uterine Fibroids Xanthenes alternative treatment base bone cancer cell cancer therapy cell killing chemotherapeutic agent chemotherapy clinical practice cytotoxic cytotoxicity design in vivo innovation killings neoplastic cell novel physical property programs public health relevance research study sound tumor

项目摘要

DESCRIPTION (provided by applicant): A novel type of therapeutic drugs which could be selectively activated by locally applied ultrasound is proposed to treat cancer and other disease. The technology is termed sonochemotherapy. The proposed sound excitable drugs (SED) are designed to have neither cytotoxicity nor phototoxicity in their native states, but having ultrasound inducible cytotoxicity. Ultrasound is a mature, safe and non-radiation technology, routinely used in various clinical imaging and treatments. Combining ultrasound with the proposed SED, the applied ultrasound wave could become a drug activator, converting non-toxic SED into cytotoxic agents to treat diseases at defined area. Different from conventional nonspecific chemotherapy, which has cytotoxic drugs circulating through out the body, sonochemotherapy provide site-specific chemotherapeutic effect. Ultrasound penetrates deep tissue emitting no radiation, thus the proposed sonochemotherapy is expected to become an alternative treatment approach of radiation therapy and photodynamic therapy with superior efficacy and safety. PUBLIC HEALTH RELEVANCE: The goal of this research is to develop a new type of tunable chemotherapeutic agents which could only be activated by specific sound wave. The proposed sonochemotherapeutic technology is unique and could have great potential in cancer treatment. If successful, it could become a safe substitute to currently used radiation therapy.

描述（由申请人提供）：一种可以通过本地应用超声选择性激活的一种新型治疗药物，以治疗癌症和其他疾病。该技术被称为正化学疗法。所提出的可激发药物（SED）的设计既不具有细胞毒性，也没有其本地状态，而是具有超声诱导的细胞毒性。超声是一种成熟，安全和非放射技术，通常用于各种临床成像和处理中。将超声与所提出的SED相结合，应用的超声波可以成为药物激活剂，将无毒的SED转化为细胞毒性剂，以治疗定义区域的疾病。与传统的非特异性化学疗法不同，该化学疗法具有细胞毒性药物在体内循环的药物，声学化学疗法提供了特定地点的化学治疗作用。超声渗透到没有放射线的深层组织中，因此，预计拟议的声学化学疗法将成为放射治疗和具有出色功效和安全性的光动力疗法的替代治疗方法。公共卫生相关性：这项研究的目的是开发一种新型的可调化学治疗剂，只能通过特定的声波激活。拟议的声学上治疗技术是独一无二的，在癌症治疗中可能具有很大的潜力。如果成功，它可能成为当前使用放射疗法的安全替代品。